Keywords: astrazeneca, remacemide, combo, potential, pd, glutamate, nmda

AstraZeneca's remacemide, combo potential for PD?

Article | 27 April 2000

AstraZeneca's remacemide, a glutamate NMDA receptor antagonist,does not improve the symptoms of Parkinson's disease when used as a monotherapy, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Astra Zeneca

AstraZeneca

Go to company listing

Related Drugs

Dopar

Levodopa

Go to drug listing